Day: August 16, 2023

SAN DIEGO, Aug. 16, 2023 (GLOBE NEWSWIRE) — Bionano Laboratories, a laboratory services business of Bionano Genomics, Inc. (Nasdaq: BNGO), today announced that it has received Laboratory Accreditation from the College of American Pathologists (CAP) for its Clinical Laboratory Improvement Amendments (CLIA)-certified reference lab. CAP accreditation is awarded to laboratories that meet stringent requirements and maintain the highest standards for laboratory operations of quality, accuracy, and consistency, as outlined by CAP. CAP accreditation is often required for a clinical service provider to become part of insurance companies’ preferred provider networks for reimbursement. It is also a credential that is frequently sought after by pharmaceutical and biotechnology companies who desire their projects to be conducted under a more...

The agreement will provide a new, wallet pass-based digital loyalty program that personalizes customer engagement and further increases taproom visits. VANCOUVER, BC, Aug. 16, 2023 (GLOBE NEWSWIRE) — Fobi AI Inc. (FOBI:TSXV) (FOBIF:OTCQB) (the “Company” or “Fobi”), an industry leader in harnessing AI and data intelligence to enable digital transformation, is pleased to announce that the Company has signed an agreement with Vancouver Island Brewing (VI Brewing) to implement a new digital loyalty program that will leverage wallet pass technology and real-time analytics to deliver more personalized and engaging taproom experiences for their customers. Fobi will earn revenue from this deal via monthly fees based on the volume of active passes. FOBI TO PROVIDE NEW DIGITAL LOYALTY PROGRAM TO INCREASE TRAFFIC AND...

Epazz, Inc.ZenaDrone 1000 flying in 120 Degree Heat in DubaiCHICAGO. IL, Aug. 16, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Epazz Inc. (OTCPINK: EPAZ), a mission-critical provider of drone technology, blockchain mobile apps and cloud-based business software solutions, announced today its reported revenue of $580,530 for the second quarter of 2023 compared to $511,633 for the second quarter of 2023. Additionally, the company reported a positive EBITDA of $132,563, compared to an EBITDA of $37,372, an increase of 71.8%. These earnings were fueled by the use of artificial intelligence (AI) engines being added to its cloud business software products. Epazz’s software products continue to generate revenue. The company has been upgrading its  technology with AI engines to assist its customers with better ways of operating their...

MILWAUKEE, Aug. 16, 2023 (GLOBE NEWSWIRE) — Twin Disc, Inc. (NASDAQ: TWIN) today reported results for the fourth quarter and full fiscal year 2023, which ended on June 30, 2023. Fiscal Fourth Quarter 2023 HighlightsSales increased 10.5% year-over-year to $83.9 million Net income attributable to Twin Disc was $8.6 million and EBITDA* of $13.0 million Significantly improved operating cash flow of $16.0 million Free cash flow* of $14.9 million compared to $(3.4) million in the year-ago period Strong six-month backlog of $119.2 million supported by healthy ongoing demandCEO Perspective“Fiscal 2023 was a tale of two halves. After facing significant supply chain headwinds and cost increases in the first half of the year, our team maintained focus and executed exceptionally. Since the start of the year, we further streamlined shipments...

Transformative Period Led by Acquisition of TeraImmune Company to Prioritize Development of New TI-168 Treg Asset for Hemophilia A Continuing to Advance Neuromuscular Blockade (NMB) Portfolio at Modest Pace Announcement of Positive Top-Line Results from Phase 2 BX1000 Trial MALVERN, Pa., Aug. 16, 2023 (GLOBE NEWSWIRE) —  Baudax Bio, Inc. (Nasdaq:BXRX) (“Baudax Bio” or the “Company”), is a biotechnology company focused on developing T cell receptor (“TCR”) therapies utilizing human regulatory T cells (“Tregs”), as well as a portfolio of clinical stage Neuromuscular Blocking Agents (“NMBs”) and an associated reversal agent, today announced results for the three and six months ended June 30, 2023 and provided a business update. “Our second quarter was a transformative period for Baudax Bio, during which we announced positive top-line...

Dallas, Texas, Aug. 16, 2023 (GLOBE NEWSWIRE) — Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug branded “Mango,” today announced the official commercial launch of its second Mango ED product, which leverages the Company’s existing custom compound alongside Sildenafil, the active ingredient found in Viagra™. Interested consumers can now proceed through the Company’s telemedicine platform and select either a Sildenafil-based Mango or the Company’s original Tadalafil-based Mango ED product, which leverages the active ingredient found in Cialis™. Both the Sildenafil and Tadalafil-based Mango ED products...

Jupiter retains 4.5 million shares in SRM Entertainment post-IPO JUPITER, FL, Aug. 16, 2023 (GLOBE NEWSWIRE) — Jupiter Wellness, Inc. (Nasdaq: JUPW), a diversified company that supports health and wellness, reported that SRM Entertainment, Inc. (“SRM”), currently a subsidiary of the Company, announced the pricing of its initial public offering of 1,250,000 shares of its common stock at a price to the public of $5.00 per share. All of the shares are being offered by SRM. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by SRM, are expected to be $6.25 million. The shares of SRMbegan trading on The Nasdaq Capital Market on August 15, 2023, under the symbol “SRM.” The offering is expected to close on August 16, 2023, subject to the satisfaction of customary...

AUSTIN, Texas, Aug. 16, 2023 (GLOBE NEWSWIRE) — QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®), for the treatment of bone cancer and related diseases, today issued the following letter to its shareholders. Dear Shareholders: We are pleased to provide you with an update on the progress and preliminary data from our Phase 1 trial studying the safety and early signs of efficacy of CycloSam® in patients with cancer that has metastasized to the bone from the breast, lung, prostate and other organs; as well as important goals we will be looking to accomplish through the end of the year. Initial Analysis of Trial Data – First Cohort In the first three patients dosed with the lowest radiation levels in our study (0.5 mCi/kg), representing...